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Abstract
Loss of the chromosomal region 8p21 negatively effects survival in patients with multiple
myeloma (MM) that undergo autologous stem cell transplantation (ASCT). In this study, we
aimed to identify the immunological and molecular consequences of del(8)(p21) with
regards to treatment response and bortezomib resistance.
In patients receiving bortezomib as a single first line agent without any high-dose ther-
apy, we have observed that patients with del(8)(p21) responded poorly to bortezomib with
50% showing no response while patients without the deletion had a response rate of 90%.
In vitro analysis revealed a higher resistance to bortezomib possibly due to an altered gene
expression profile caused by del(8)(p21) including genes such as TRAIL-R4, CCDC25,
RHOBTB2, PTK2B, SCARA3, MYC, BCL2 and TP53. Furthermore, while bortezomib sen-
sitized MM cells without del(8)(p21) to TRAIL/APO2L mediated apoptosis, in cells with del
(8)(p21) bortezomib failed to upregulate the pro-apoptotic death receptors TRAIL-R1 and
TRAIL-R2 which are located on the 8p21 region. Also expressing higher levels of the decoy
death receptor TRAIL-R4, these cells were largely resistant to TRAIL/APO2L mediated
apoptosis.
Corroborating the clinical outcome of the patients, our data provides a potential explana-
tion regarding the poor response of MM patients with del(8)(p21) to bortezomib treatment.
Furthermore, our clinical analysis suggests that including immunomodulatory agents such
as Lenalidomide in the treatment regimen may help to overcome this negative effect, provid-
ing an alternative consideration in treatment planning of MM patients with del(8)(p21).
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Introduction
Multiple Myeloma (MM) is a malignant neoplasm that accounts for about 20% of deaths
caused by hematological malignancies and is characterized by clonal proliferation of plasma
cells in the bone marrow (BM). The current gold standard for the treatment of patients under
65 years of age is high-dose chemotherapy (HDT) followed by autologous stem cell transplan-
tation (ASCT)[1]. In the last decade, the addition of novel agents such as the proteasome inhib-
itor bortezomib (Velcade1) to the regimen has resulted in a substantial increase in the
number of patients responding to therapy[2]. Following these results, bortezomib is included
in almost all the treatment regimens in the 1st line treatment of MM patients and is currently
considered to be the backbone in modern treatment of MM patients. Yet, approximately 20%
of patients do not respond to bortezomib[3]. Defining a mechanism of drug resistance in these
patients may have a direct implication on the choice of treatment modality.
While bortezomib exerts its major activity by inhibiting the chymotrypsin-like proteolytic
activity of the 26S proteasome and promoting the accumulation of inefficiently degraded pro-
teins leading to apoptosis, several studies have also shown that it is a key player in sensitization
of MM cells to apoptosis induced by TRAIL/APO2L via upregulation of TRAIL receptors 1
and 2[4].
We have recently discovered that loss of the chromosomal region 8p21 is an independent
prognostic factor associated with poor survival in MM patients receiving standard ASCT[5, 6].
These findings have been confirmed by other groups who have reported similar results[7, 8].
The tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor gene cluster as
well as several other genes such as PTK2B[9] and SCARA3[10] that might have a role in multi-
ple myeloma progression and treatment resistance, lie in the p arm of chromosome 8. However,
the effect of the deletion on the bortezomib resistance and bortezomib mediated sensitization
to TRAIL/APO2L killing has been left as a speculation so far. While the alteration of cell sur-
face TRAIL receptor expression due to del(8)(p21) might cause decreased sensitivity of tumor
cells to TRAIL-mediated apoptosis[11] [12], it must be noted that these clones still carry one
copy of each TRAIL-R gene, since the deletion in the 8p21 region is almost exclusively monoal-
lelic. Therefore, bortezomib treatment might still upregulate TRAIL receptor expression and
break immune tolerance resulting in efficient elimination of MM cells with 8p21 deletion.
In this study, in order to identify the consequences of del(8)(p21), with a special focus on
TRAIL/APO2L mediated killing, we have analyzed the expression of various genes on the 8p21
region as well as others in patients with and without del(8)(p21). Additionally, we have ana-
lyzed the response of MM cells with and without the deletion to bortezomib mediated killing
and sensitization to TRAIL/APO2L triggered apoptosis in an attempt to understand why MM
patients carrying 8p21 deletion respond poorly to bortezomib treatment.
Materials and Methods
Patient material and cell lines
The patients were admitted to the Department of Medicine, Karolinska University Hospital
Huddinge, Stockholm, Sweden. This study was specifically approved by the local research eth-
ics committee (Etikprövningsnämnden Stockholm, Ethical permit number: 2014/526-31).
Written informed consent was obtained from all patients in accordance with the Declaration of
Helsinki and with the local ethical committee guidelines.
Bone marrow aspirates at diagnosis were separated by density gradient centrifugation (Lym-
phoprepTM, Axis-Shield, Oslo, Norway). Plasma cells were positively selected by CD138 mag-
netic beads using AutoMACS (Miltenyi Biotec, Bergisch Gladbach, Germany). K562 and U266
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cells were maintained in RPMI 1640 medium (GIBCO
1
, Life Technologies, Carlsbad, CA) sup-
plemented with 10% FBS (GIBCO).
Analysis of mRNA levels
A TaqMan
1
array micro fluidic card (TLDA, Applied Biosystems
1
, Life Technologies) was
designed in order to study the expression of a selected set of genes on the 8p21 region as well as
some additional genes that were reported to be overexpressed in MM[13] and had functional
links to genes located on the 8p21 region. The full list of genes and TaqMan
1
assay IDs can be
found in S1 Table.
Total RNA was extracted from TRIZOL
1
(Life Technologies) treated CD138+ magnetically
separated bone marrow cells and RNA was isolated using RNeasy Plus Mini Kit (Qiagen, Lim-
burg, the Netherlands) according to manufacturer’s protocol. 800 ng of total RNA was used for
cDNA synthesis using Superscript III (Invitrogen) according to manufacturer’s protocol. The
reaction mixture containing 50 μl cDNA template (200 ng) and an equal volume of TaqMan
1
universal master mix (Applied Biosystems) was added to each line of TLDA after gentle vortex
mixing. The samples were run as triplicates on a 79000HT Fast-Real-Time PCR System
(Applied Biosystems) and the cycling conditions were as follows: 2 min at 50°C, 10 min at
94.5°C and 30 s at 97°C, and 1 min at 59.7°C for 40 cycles.
Analysis was done using DataAssist software (Life Technologies) and threshold cycle Ct was
automatically determined. The expression of GAPDH and ACTB genes were used as endoge-
nous control genes while RNA samples from K562 and U266 cell lines were used as calibrator
samples to analyze relative gene expression in the patient samples. Data derived from the
TLDA were normalized against the average values of the control genes. Relative quantities
(RQ) were determined using the equation: RQ = 2-ddCt.
Analysis of TRAIL receptor cell surface expression
CD138+ plasma cells or CD138- bone marrow mononuclear cells (BM-MNC) were cultured in
RPMI 1640 medium supplemented with 10% FBS in the presence or absence of 10 nM bortezo-
mib for 24 hours in U-bottom 96-well plates. Cells were washed with PBS and stained with
fluorescently labeled anti-TRAIL receptor antibodies, TRAIL-R1 (DR-4-02), TRAIL-R2
(DR5-01-1), TRAIL-R3 (TRAIL-R2-02) and TRAIL-R4 (TRAIL-R4-01) (Thermo Scientific);
anti-CD38 (HIT2, BD Biosciences, San Jose, CA) and anti-CD138 (MI15, BD Biosciences),
additionally CD138- BM-MNC were stained with anti-CD45 (HI30, BD Biosciences) antibody
30 minutes on ice. The cells were then washed and resuspended in PBS at 4°C. Relative expres-
sion of each TRAIL receptor was normalized by MFI of corresponding isotype control.
Analysis of apoptosis upon bortezomib and/or soluble TRAIL treatment
CD138+ cells were cultured in RPMI with 10% FBS overnight, together with or without 10 nM
bortezomib followed by a 6 hour incubation with 250 ng/ml soluble TRAIL/APO2L. The cells
were stained with anti-CD138 and anti-CD38 antibodies for 30 minutes on ice followed by
Annexin V and propidium iodide (PI) staining according to manufacturer’s instructions (BD
Biosciences). Percentage of Annexin V-PI-CD38+CD138+ plasma cells in samples that were not
incubated with bortezomib and TRAIL/APO2L were used as controls. All flow cytometry data
was acquired using CyFlow ML (Partec, Munster, Germany) and analyzed by Flowjo software
(Tree Star, Ashland, OR, USA).
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Analysis of chromosomal abnormalities by fluorescent in situ
hybridization (FISH)
CD138+ plasma cells (2–4 x 104 cells/spot) were centrifuged to prepare hybridization slides
using CytoSpin (Thermo Scientific, Pittsburg, PA), air-dried overnight and stored at -20°C. For
FISH analysis, all cases were investigated with in vitro diagnosis certified probe sets targeting
1q21/8p21, 6q21/15q22, 17p13.1/19q13, 9p21/9q21, 13q14/qter, and for translocations t(4;14)
(p16.3;q32.3), t(11;14)(q13;q32.3), t(14;16)(q32.3;q23) (Kreatech, Amsterdam, the Nether-
lands). Hybridization and detection of signals were performed according to the manufacturer’s
protocols. Analysis of spot counting was done in Olympus microscope (BX60, Tokyo, Japan).
200 nuclei were evaluated for each probe. Full list of patient specific chromosomal abnormali-
ties observed in this study is listed in S3 and S4 Tables.
Patients and treatment
140 consecutive patients diagnosed with MM at our hospital between 2008 until the end of
December 2012 were included of which 37 patients (26%) had del(8)(p21). Patients with
plasma cell leukemia or solitary plasmacytoma were excluded. Eighty eight of the 140 patients
were treated with bortezomib in 1st line, 24 with del(8)(p21) and 64 without. Bortezomib based
induction was given as VCD (bortezomib/Cyclophosphamide/Dexamethasone) and followed
by conditioning with melphalan (200 mg/m2) to all HDT patients. The non-HDT population
received either VCD (69%) or VMP (bortezomib/Melphalan/Dexamethasone) (31%). 34
patients were treated in 2nd line with Lenalidomide and Dexamethasone; 16 with prior bortezo-
mib treatment in 1st line and no HDT and 18 with VCD induction and HDT. Response to
treatment was evaluated according to Blade et al [14].
Statistical Analysis
Graphs and statistical analysis were done by GraphPad Prism (GraphPad Software Inc. La
Jolla, CA, USA). Log-rank (Mantel-cox) test was used for Fig 1. Unpaired t-test was used to
analyze Fig 2. Wilcoxon rank tests and Mann-Whitney tests were used to analyze the results
for Figs 3 and 4. The data for Figs 3 and 4 are presented in S5 Table. Chi-square test was per-
formed to analyze results in Fig 5.
Results
Deletion at the chromosomal region 8p21 results in poor survival
We have previously reported that the loss of 8p21region was significantly associated with poor
progression-free survival (PFS) and overall survival (OS) in a cohort of MM patients that were
diagnosed in our clinic [6]. Here, we analyze a larger cohort of patients that were diagnosed
with multiple myeloma between 2008 and 2012 (37 with del(8)(p21) and 103 without deletion)
(Table 1). Univariate analysis of patient data did not show any significant difference in any
parameter at diagnosis except skeletal destruction. Patients with del(8)(p21) had significantly
higher bone lesions (76%) compared to 55% in patients without the deletion (p = 0.027)
(Table 1).
In this cohort, 88 patients were treated with bortezomib as first line agent and we find that
MM patients carrying 8p21 deletion had significantly shorter time to progression (TTP) com-
pared to patients without the deletion (p = 0.0159) (Fig 1A) and most importantly these
patients had significantly shorter overall survival (OS) compared to patients without the dele-
tion (p = 0.0219) (Fig 1D), with a hazard ratio of 2.043 (1.18–4.74) and 2.96 (1.22–11.64),
respectively. Furthermore, OS of myeloma patients carrying 8p21 deletion that underwent
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Fig 2. Quantitative RT-PCR analysis of gene expression in MM patients with or without del(8)(p21). TLDA cards were used to analyze mRNA levels in
patients with (n = 19) and without (n = 6) del(8)(p21). For the analysis, GAPDH and ACTB genes were used as endogenous controls while RNA samples from
K562 and U266 cell lines were used as calibrators. (*p<0.05, unpaired t test) (A) The mRNA level relative expression of TRAIL receptors in patients with and
without the deletion. TRAIL-R1,-R2 and–R3 did not show any change while TRAIL-R4 was expressed at significantly higher levels in patients carrying the
deletion. (B) Genes on or near 8p21 (C) other analyzed genes located elsewhere in the chromosome that show at least two-fold differential expression in MM
cells with the deletion. Depicted are the gene expression levels in MM cells carrying the deletion, normalized to samples without the deletion.
doi:10.1371/journal.pone.0138248.g002
Fig 1. Multiple myeloma patients with del(8)(p21) have poor TTP and OS. Time to progression (TTP) of (A) all patients, (B) HDT patients, (C) non-HDT
patients after diagnosis (months). Overall survival (OS) of (D) all patients, (E) HDT patients, (F) non-HDT patients after diagnosis (months). Patients with del
(8)(p21) (n = 24). Patients without del(8)(p21) (n = 64). HDT patients with del(8)(p21) (n = 14). HDT patients without del(8)(p21) (n = 41). Non-HDT patients
with del(8)(p21) (n = 10). Non-HDT patients without del(8)(p21) (n = 23). Log-rank (Mantel-cox) test performed using Graphpad Prism software.
doi:10.1371/journal.pone.0138248.g001
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HDT had significantly decreased compared to patients without the deletion (Fig 1B and 1E).
On the other hand, patients that are not eligible for HDT showed no significant difference in
OS or TTP (Fig 1C and 1F).
In multivariate analysis del(8)(p21) presented as an independent prognostic factor associ-
ated with poor overall survival in agreement with our prior observations (Table 2). Conse-
quently, these results confirm ours and others’ previous observations that del(8)(p21)
negatively affects the prognosis of MM patients.
Fig 3. Patients with del(8)(p21) fail to upregulate pro-apoptotic TRAIL receptor expression upon bortezomib treatment.Relative expression of TRAIL
receptors of 5 MM patients with del(8)(p21) and 7 MM patients without deletion is determined by flow cytometry. Cell surface Expression levels are
normalized to corresponding isotype controls. (A) TRAIL-R1, (B) TRAIL-R2, (C) TRAIL-R3, (D) TRAIL-R4. Effect of bortezomib treatment on TRAIL receptor
expression is analyzed by paired t-test.
doi:10.1371/journal.pone.0138248.g003
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Deletion at the chromosomal region 8p21 leads to altered gene
expression in primary MM cells
In order to identify the changes associated with del(8)(p21), expression levels of a certain set of
genes were comparatively analyzed in patients with or without the deletion by quantitative
real-time PCR (S1 Table).
Fig 4. Patients with del(8)(p21) are less sensitive to bortezomib and TRAILmediated apoptosis.CD138 expression levels and Annexin V/PI staining
was performed to assess viable, apoptotic and dead cells. Mononuclear cells were separated by Lymphoprep from fresh bone marrow aspirates of MM
patients followed by CD138 positive magnetic selection. Cells were incubated overnight with or without 10 nM bortezomib followed by incubation with or
without 250 ng/ml soluble TRAIL/APO2L for 6 hours. Thereafter, cells were stained with anti-CD38, anti-CD138, anti-Annexin V antibodies and PI. (A)
Representative patient data displaying relative changes in CD38+/CD138Bright cell population (left panel) and Annexin V/PI (right panel) upon bortezomib
and/or soluble TRAIL/APO2L treatment. (B) Relative changes in the CD38+/CD138Bright cell population of 13 MM patients without del(8)(p21) and 6 MM
patients with del(8)(p21) upon bortezomib and/or soluble TRAIL/APO2L treatment is displayed. Amount of CD38+/CD138Bright cells of each untreated patient
MM cells is considered as 100%. (C) Relative percentage of live MM cells (Annexin V- and PI- cells) of 13 MM patients without del(8)(p21) and 6 MM patients
with del(8)(p21) is displayed. Percentage of untreated live MM cells is considered as 100%. Statistical analysis of bortezomib and/or TRAIL treatment is
assessed with Wilcoxon rank test in patients with or without del(8)(p21). * P<0.05, ** P<0.01, *** P<0.001. Mann-Whitney test was performed to compare
patients groups with and without del(8)(p21). # P<0.05. Median values for each group are displayed in B and C.
doi:10.1371/journal.pone.0138248.g004
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When the two sets of patients were compared for the mRNA levels of these genes, several
cases of differential expression were observed (Fig 2). At the mRNA level, patients with del(8)
(p21) showed similar levels of expression for TRAIL-R1,-R2 and R3 while they showed signifi-
cantly upregulated expression of TRAIL-R4 when compared to patients without del(8)(p21)
Fig 5. Patients with 8p21 deletion respond poorly to bortezomib treatment. Patients diagnosed with MM and receiving bortezomib based treatment at
1st line were selected to this study (n = 88). (A) left panel is the non-HDT patients that received bortezomib (Vel: Velcade1, n = 33) as 1st line treatment and
right panel is the non-HDT patients that did not respond to 1st line bortezomib treatment or relapsed and treated with Lenalidomide based regimen as a 2nd
line treatment (n = 16). B. Left panel displays patients received high dose treatment and bortezomib as 1st line treatment (n = 55) and right panel is the
response to Lenalidomide based treatment as 2nd line for relapse patients (n = 18). Details of the treatments are shown in materials & methods section. Chi-
square test was performed to analyze results.
doi:10.1371/journal.pone.0138248.g005
Table 1. Univariate analysis of clinical parameters of multiple myeloma patients.
Patients with del(8)(p21) Patients without del(8)(p21)
n Mean (SD) n Mean (SD) p value
Gender (male) 37 57% 103 39% 0.069
Age (y) 37 63 (10.3) 103 60 (10.8) 0.160
Bone disease (present) 37 76% 102 55% 0.027
s-Calcium 36 2.47 (0.31) 94 3.49 (10.2) 0.548
Hemoglobin 36 106 (23.1) 95 112 (21.0) 0.134
β2M 35 4.7 (4.07) 95 5.7 (11.4) 0.630
s-Albumin 36 34 (5.81) 94 32 (5.21) 0.121
s-Creatinine 36 141 (208) 99 123 (128) 0.542
doi:10.1371/journal.pone.0138248.t001
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(Fig 2A). These results indicate that while del(8)(p21) is expected to affect the expression levels
of genes located in the region, the TRAIL receptor gene cluster is minimally affected, with no
changes in mRNA levels of three genes and upregulation of the decoy receptor, TRAIL-R4.
As expected, the expression of several genes located on or near the 8p21 region were signifi-
cantly altered in patients carrying del(8)(p21) (Fig 2B). Of the analyzed genes, DOCK5,
IKBKB, CCDC25, CEBPD, RHOBTB2, KIAA1967, PHYHIP and SCARA3 showed statistically
significant downregulation of at least two-fold. More interestingly, three of the analyzed genes
located on 8p21 (TRAIL-R4, PTK2B and SLC39A14) showed at least two-fold upregulated
mRNA levels despite the possible deletion of one gene copy.
Genes located elsewhere on the genome also showed differential expression in patients with
del(8)(p21) compared to patients without the deletion. As presented in Fig 2C, genes with
oncogenic potential such as MYC, BCL2 and RINT1 were upregulated while the tumor sup-
pressor TP53 was downregulated. Genes involved in chromatin remodeling such as SMARCA4
(BRG1) and CHD3 as well as genes involved in immune function such as NFKB1 and LPXN
also showed differential expression in patients with del(8)(p21).
In order to identify the effect of other commonly seen chromosomal aberrations, we ana-
lyzed the gene expression data with regards to other commonly observed chromosomal abnor-
malities in this cohort of patients (S2 Table). This analysis has revealed that the deregulated
expression of the MYC oncogene is also associated with 1q21, 11q13, 15q22, 19q13 and 13q
aberrations, the downregulation of KIAA1967 is also associated with chromosome 9q21, 11q13
and 15q22 aberrations and upregulation of BCL2 is also associated with 15q22 amplification.
Patients with del(8)(p21) fail to upregulate pro-apoptotic TRAIL receptor
expression upon bortezomib treatment
We next determined changes in the cell surface expression levels of the pro-apoptotic receptors
TRAIL-R1 and R2, as well as the anti-apoptotic decoy receptors TRAIL-R3 and R4 upon in
vitro bortezomib treatment in MM cells with or without del(8)(p21) (Fig 3).
CD138+ myeloma cells expressed similar levels of TRAIL-R1 regardless of del(8)(p21) sta-
tus, in line with mRNA expression results. While a similar trend of TRAIL-R4 upregulation
was observed in patients with del(8)(p21), this did not reach statistical significance possibly
due to the use of a smaller sample size for flow cytometric phenotyping.
More interestingly, while 24 hour bortezomib treatment (10nM) could successfully upregu-
late TRAIL-R1 expression in MM cells of patients without del(8)(p21) (1.31 fold, p = 0.0059),
MM cells from patients with del(8)(p21) failed to upregulate the pro-apoptotic TRAIL-R1
expression (1.11 fold, p = 0.1254) (Fig 3A). Furthermore, bortezomib treatment did not have
any impact on expression levels of TRAIL-R2 in patients with (1.11 fold, p = 0.6739) or without
Table 2. Multivariate analysis of prognostic factors in multiple myeloma patients.
OS TTP
p Relative risk (95% CI) p Relative risk (95% CI)
del(8)(p21) 0.010 4.904 (1.467–16.396) 0.187 1.635 (0.788–3.393)
gain(1q), t(4;14), t(14;16), del17p 0.270 1.969 (0.591–6.568) 0.600 1.187 (0.625–2.254)
s-Calcium 0.319 0.915 (0.769–1.089) 0.005 0.882 (0.809–0.962)
Hemoglobin 0.301 1.012 (0.989–1.036) 0.972 1.000 (0.986–1.015)
β2M 0.457 1.054 (0.918–1.209) 0.004 1.137 (1.042–1.241)
s-Albumin 0.135 0.920 (0.826–1.026) 0.906 0.996 (0.936–1.061)
s-Creatinine 0.736 0.999 (0.996–1.003) 0.233 0.998 (0.996–1.001)
doi:10.1371/journal.pone.0138248.t002
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(1.06 fold, p = 0.2165) del(8)(p21) (Fig 3B). Although bortezomib treatment of myeloma cells
displayed a statistically non-significant trend of TRAIL-R3 upregulation in patients without
8p21 deletion (1.46 fold, p = 0.0697), it did not have any impact on cells carrying the deletion
(0.92 fold, p = 0.1855)(Fig 3C). Likewise, the expression of TRAIL-R4 was not affected by bor-
tezomib treatment regardless of del(8)(p21) status (no del(8)(p21) 1.14 fold, p = 0.2947; del(8)
(p21) 0.81 fold, p = 0.2242) (Fig 3D).
Taken together, these data indicate that upon bortezomib exposure, the most important and
significant difference is, unlike the cells without the deletion, MM cells carrying del(8)(p21) fail
to upregulate the pro-apoptotic TRAIL-R1.
Changes observed in TRAIL receptor levels were mainly myeloma specific since expression
of TRAIL receptors in CD138-/CD45+compartment of bone marrow did not get affected by
bortezomib treatment irrespective of del(8)(p21) status (S1 Fig). Thus, these results indicate
that bortezomib treatment could not efficiently sensitize myeloma cells with del(8)(p21) to
TRAIL mediated apoptosis.
Patients with del(8)(p21) are less sensitive to bortezomib and TRAIL
mediated apoptosis
It has been previously demonstrated that bortezomib treatment can upregulate TRAIL recep-
tors in various tumor types, which can result in sensitization of these cells to TRAIL mediated
apoptosis[4, 15]. Here, sensitivity of myeloma cells with or without del(8)(p21) to bortezomib
and soluble TRAIL/APO2L is assessed in order to evaluate the impact of differential gene
expression driven by 8p21 deletion, such as TRAIL-R4, on myeloma cell survival. Downregula-
tion of CD138, which is one of the early markers of apoptosis in myeloma cells and the percent-
age of CD38+/CD138Bright primary MM cells[16] as well as the amount of viable, apoptotic and
dead cells were assessed simultaneously by flow cytometry (Fig 4).
In myeloma cells without del(8)(p21), bortezomib alone and soluble TRAIL/APO2L alone
efficiently induced a decrease in CD38+/CD138Bright MM cells as well as apoptosis. More
importantly, the combination of bortezomib and TRAIL treatment significantly increased apo-
ptosis and decrease the number of CD38+/CD138Bright MM cells (Fig 4B and 4C), implying
that bortezomib treatment can further sensitize myeloma cells without 8p21 deletion to
TRAIL-mediated killing.
While bortezomib treatment slightly affected the ratio of CD38+/CD138Bright MM cells, it
failed to induce apoptosis on myeloma cells with 8p21 deletion, either alone or in combination
with soluble TRAIL/APO2L (Fig 4B and 4C). Additionally, we have employed a similar
approach and analyzed the data by grouping the patients according to other commonly
observed chromosomal abnormalities including amp11q13, amp1q21, amp15q22 and del13q.
Only when the grouping was done according to 8p21 status, there was significant difference in
the response to in vitro bortezomib and TRAIL (S2 Fig).
Thus, our in vitro analysis revealed that a higher proportion of cells from myeloma patients
carrying the 8p21 deletion are less sensitive to both bortezomib and TRAIL mediated killing
than myeloma cells from patients without the deletion. Therefore it is essential to assess the
clinical impact of bortezomib treatment on MM patients with del(8)(p21).
Patients with del(8)(p21) respond poorly to bortezomib treatment
During our in vitro observations that MM cells carrying the del(8)(p21) responded poorly to
bortezomib or bortezomib mediated sensitization to TRAIL/APO2L killing, we sought to
investigate whether this phenomenon showed any effect in the clinical response of patients car-
rying the deletion. In order to ascertain the effect of bortezomib alone, we have primarily
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investigated the response of patients that were not eligible for HDT and received bortezomib as
a first-line treatment (Fig 5A). The clinical response to bortezomib as a first-line agent clearly
demonstrates that patients with del(8)(p21) respond very poorly, with about half the patients
showing no response (NR) at all and less than 10% of them showing very good partial remis-
sion (VGPR) or better. On the contrary, the patients without the deletion have a much better
response to bortezomib, with more than 50% of the patients achieving VGPR or better and
only about 10% of the patients showing NR (p = 0.0216). Interestingly, when the patients that
are not eligible for HDT relapsed and received Lenalidomide as a second line treatment (Fig
5A), the response of patients with the deletion significantly surpassed those without the dele-
tion (p = 0.0302), indicating that despite their poor response to bortezomib, patients with the
deletion might still benefit greatly from Lenalidomide treatment if HDT is not an option. On
the other hand, we have found that in patients receiving HDT, the negative effect of 8p21 dele-
tion on patient response is largely, if not fully, overcome with a non significant difference in
response between patients with and without del(8)(p21) (p = 0.2579) (Fig 5B). When patients
receiving HDT relapsed and received Lenalidomide as a second-line treatment, there was little
difference between the patient groups, with slightly lower levels of del(8)(p21) carrying patients
achieving VGPR or better (p = 0.4640).
Taken together, these data indicate that patients with del(8)(p21) clinically have a poor
response to bortezomib treatment, which might be possible to improve by using HDT or
administration of immunomodulatory drugs such as Lenalidomide at an earlier stage of the
disease.
Discussion
Recent years have witnessed a significant increase in the survival rates for MM patients due to
the introduction of combination therapies including proteasome inhibitors such as bortezomib
and immunomodulatory drugs such as thalidomide, and lenalidomide [17]. Bortezomib has
been proven to be the most efficient 1st line therapy regimen but approximately 20% of patients
still do not respond to bortezomib treatment and underlying mechanisms that lead to bortezo-
mib resistance are currently being scrutinized in detail[18–20]. However, immunological
aspects of this resistance have been largely omitted.
In this study, we have investigated the molecular consequences of 8p21 deletion, which is
seen in approximately 20% of MM patients[5–8] and its potential link to resistance against bor-
tezomib treatment. Since the exact position of the chromosomal break is unknown and possi-
bly differs from patient to patient, we have selected for analysis, a set of genes located on or
nearby the 8p21 region that might be essential for tumor survival and bortezomib resistance.
This set of genes was further enlarged by the addition of other targets which showed differential
expression in prior gene expression profiling studies on MM cells[13] and could be functionally
linked to one or more genes located on or near the 8p21 region.
The pro-apoptotic TRAIL receptors, TRAIL-R1 and TRAIL-R2, as well as the decoy recep-
tors TRAIL-R3 and TRAIL-R4 are located in the 8p21 region. Despite the expectation that los-
ing one copy of the region would significantly diminish the expression of genes located here,
we surprisingly did not observe any significant changes for TRAIL-R1, R2 and R3 at the
mRNA level compared to patients without the deletion while an elevated expression of anti-
apoptotic TRAIL-R4 was seen. We have observed the decreased expression of TP53[21] which
directly affects TRAIL-R2 levels in myeloma cell lines[22] but decreased TP53 expression in
MM cells carrying del(8)(p21) did not lead to downregulation of TRAIL-R2 expression neither
at the mRNA level nor at the cell surface. Previous studies did not always indicate a direct cor-
relation between TRAIL receptor expression and TRAIL mediated apoptosis in tumor models
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[15, 23, 24] since other factors such as the expression levels and activities of NFkB and BCL-2
also play important roles in bortezomib resistance[25–27] as well as TRAIL mediated apopto-
sis[12, 28, 29]. Here we show that both BCL-2 and NFkB mRNA levels are increased in MM
cells with del(8)(p21) (Fig 2). Along with the high expression of the MYC oncogene that has
been shown to promote MM cell survival[30–32], in MM cells carrying the 8p21 deletion, we
have observed the upregulated expression of PTK2B (Pyk2 or RAFTK) which was recently
demonstrated to promote tumor progression in MM[9]. Additionally, the diminished expres-
sion of SCARA3, which is negatively correlated with multiple myeloma prognosis[10] together
with the aforementioned changes of gene expression in cells carrying the deletion might pro-
vide a platform that promotes myeloma cell survival.
It must be noted that, del(8)(p21) is commonly seen together with a range of other recurrent
chromosomal abnormalities that might influence global gene expression profile. For 17p13
aberrations in the present cohort, we observed 2/19 of patients with del(8)(p21) carry a deletion
and 1/6 of patients without del(8)(p21) carry an amplification while t(4;14) was observed in 2/
19 of patients with del(8)(p21) and 1/6 of patients without del(8)(p21). Due to the low number
of patients carrying these additional chromosomal abnormalities, the data presented in this
study can neither confirm nor reject the presence of any effect that might be due to the global
gene expression changes caused by del(17)(p13) or t(4;14)[33, 34].
Regarding other chromosomal abnormalities commonly seen in this cohort of patients, our
analysis (S2 Table) reveals that the gene expression changes of MYC, KIAA1967 and BCL2 are
also associated with the presence of other chromosomal abnormalities and cannot be attributed
to del(8)(p21) alone.
In line with previous observations that bortezomib upregulates the expression of death
receptors TRAIL-R1 and-R2[35–37], we observed that bortezomib treatment significantly
upregulated cell surface expression of TRAIL-R1 in MM cells that do not carry the del(8)(p21),
making them vulnerable to TRAIL mediated apoptosis. However, MM cells carrying del(8)
(p21) failed to upregulate death receptors upon bortezomib treatment (Fig 3A and 3B) while
keeping steady levels of pro-survival receptors TRAIL-R3 and-R4. Consequently, soluble
TRAIL/APO2L and bortezomib failed to induce apoptosis efficiently whether used alone or in
combination on MM cells carrying the deletion (Fig 4). It is essential to investigate the in vitro
cytotoxic impact of other drugs, which are used in treatment of MM such as Melphalan and
Dexamethasone, on myeloma cells carrying 8p21 deletion. It is noteworthy that in cells with
del(8)(p21), a slight decrease in CD38+/CD138Bright MM cells, which could be an early marker
of apoptosis in myeloma cells, was observed. These results support the hypothesis that del(8)
(p21) triggers an apoptotic resistance mechanism that uncouples CD138 downregulation from
apoptotic cell death, so despite the decrease in the amount of CD38+/CD138Bright MM cells,
efficient triggering of apoptotic pathways is lacking.
It should also be noted that even though bortezomib has potential to sensitize tumor cells to
TRAIL mediated apoptosis, it has also been shown to negatively affect T cell and NK cell func-
tion[38, 39]. Conversely, the immunomodulatory drug Lenalidomide upregulates TRAIL
expression on NK cells, which might enhance TRAIL mediated killing of myeloma cells[40,
41]. Our clinical data also shows that while bortezomib largely fails to elicit a good response in
patients carrying del(8)(p21), Lenalidomide treatment as second line reverts this negative effect
(Fig 5).
To conclude, our results demonstrate that the changes associated with del(8)(p21) in MM,
might be the foundation of resistance to bortezomib treatment and resistance against bortezo-
mib mediated sensitization to TRAIL/APO2L killing. This is strongly supported by clinical
data which demonstrates the poor response of the patients with del(8)(p21) to bortezomib as a
first line treatment and calls for the incorporation of agents such as Lenalidomide into the
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treatment regimen in order to avert the negative impact of 8p21 deletion on patient survival,
but should be further investigated with randomized trials.
Supporting Information
S1 Fig. Bortezomib does not alter TRAIL receptor expression of CD138- BM cells.
(DOCX)
S2 Fig. Analysis of sensitivity to bortezomib and TRAIL mediated apoptosis within differ-
ent chromosomal abnormalities.
(DOCX)
S1 Table. List of genes analyzed by quantitative RT-PCR.
(DOCX)
S2 Table. Analysis of gene expression data according to chromosomal abnormalities com-
monly seen in this patient cohort.
(DOCX)
S3 Table. Chromosomal abnormalities of patients used in TLDAmRNA analysis
(DOCX)
S4 Table. Chromosomal abnormalities of patient cells used in TRAIL-R cell surface expres-
sion and apoptosis assays.
(DOCX)
S5 Table. Summary of data for Figs 3 and 4.
(DOCX)
Acknowledgments
This research was supported by generous grants of the Swedish Cancer Fund (Cancerfonden),
Swedish Cancer Society in Stockholm (Cancerföreningen/ Radiumhemmets forskningsfonder),
Swedish Research Council, VINNOVA, Karolinska Institutet Foundation and State of Florida
Department of Health. We would like to thank Mari Gilljam and research nurses at Karolinska
University Hospital Huddinge for their assistance.
Author Contributions
Conceived and designed the experiments: ADD TS GG EA HN. Performed the experiments:
ADD TS AW BS. Analyzed the data: ADD TS HN KU JL. Contributed reagents/materials/anal-
ysis tools: HN KU JL. Wrote the paper: ADD TS GG EA HN.
References
1. Harousseau JL, Shaughnessy J Jr., Richardson P. Multiple myeloma. Hematology Am Soc Hematol
Educ Program. 2004:237–56. Epub 2004/11/25. doi: 10.1182/asheducation-2004.1.237 PMID:
15561686.
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in
multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5):2516–20. Epub 2007/11/03.
doi: 10.1182/blood-2007-10-116129 PMID: 17975015; PubMed Central PMCID: PMC2254544.
3. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus
melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906–
17. Epub 2008/08/30. doi: 359/9/906 [pii] doi: 10.1056/NEJMoa0801479 PMID: 18753647.
8p21 Deletion Confers Bortezomib Resistance in Multiple Myeloma
PLOSONE | DOI:10.1371/journal.pone.0138248 September 17, 2015 13 / 16
4. deWilt LH, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FA. Bortezomib and TRAIL: a perfect
match for apoptotic elimination of tumour cells? Crit Rev Oncol Hematol. 85(3):363–72. Epub 2012/09/
05. doi: S1040-8428(12)00167-9 [pii] doi: 10.1016/j.critrevonc.2012.08.001 PMID: 22944363.
5. Sutlu T, Alici E, Gahrton G, Nahi H. In search of the molecular consequences of 8p21 deletion in multi-
ple myeloma: commentary on Gmidene et al. Medical oncology. 2013; 30(2):569. Epub 2013/04/10.
doi: 10.1007/s12032-013-0569-9 PMID: 23568164.
6. Sutlu T, Alici E, JanssonM, Wallblom A, Dilber MS, Gahrton G, et al. The prognostic significance of
8p21 deletion in multiple myeloma. Br J Haematol. 2009; 144(2):266–8. Epub 2008/11/20. doi:
BJH7454 [pii] doi: 10.1111/j.1365-2141.2008.07454.x PMID: 19016723.
7. Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, et al. Combining information regard-
ing chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classifica-
tion allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Haematologica. 2010; 95(7):1150–7. Epub 2010/03/12. doi: 10.3324/haematol.2009.016436 PMID:
20220069; PubMed Central PMCID: PMC2895040.
8. Gmidene A, Saad A, Avet-Loiseau H. 8p21.3 deletion suggesting a probable role of TRAIL-R1 and
TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma. Medical
oncology. 2013; 30(2):489. doi: 10.1007/s12032-013-0489-8 PMID: 23423784.
9. Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, ZhangW, et al. Pyk2 promotes tumor progression
in multiple myeloma. Blood. 2014; 124(17):2675–86. doi: 10.1182/blood-2014-03-563981 PMID:
25217697; PubMed Central PMCID: PMC4208283.
10. Brown CO, Schibler J, Fitzgerald MP, Singh N, Salem K, Zhan F, et al. Scavenger receptor class A
member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma. Leukemia
research. 2013; 37(8):963–9. Epub 2013/03/30. doi: 10.1016/j.leukres.2013.03.004 PMID: 23537707;
PubMed Central PMCID: PMC3700682.
11. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived frommultiple myeloma
patients and is not cytotoxic to hematopoietic stem cells. Leukemia. 1999; 13(11):1817–24. Epub 1999/
11/11. PMID: 10557057.
12. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H, et al. Critical role for tumor necro-
sis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp
Med. 2002; 195(2):161–9. Epub 2002/01/24. PMID: 11805143.
13. Shaughnessy JD Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene
expression model of high-risk multiple myeloma is defined by deregulated expression of genes map-
ping to chromosome 1. Blood. 2007; 109(6):2276–84. Epub 2006/11/16. doi: 10.1182/blood-2006-07-
038430 PMID: 17105813.
14. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating dis-
ease response and progression in patients with multiple myeloma treated by high-dose therapy and
haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for
Blood and Marrow Transplant. Br J Haematol. 1998; 102(5):1115–23. Epub 1998/09/30. PMID:
9753033.
15. Balsas P, Lopez-Royuela N, Galan-Malo P, Anel A, Marzo I, Naval J. Cooperation between Apo2L/
TRAIL and bortezomib in multiple myeloma apoptosis. Biochemical pharmacology. 2009; 77(5):804–
12. Epub 2008/12/23. doi: 10.1016/j.bcp.2008.11.024 PMID: 19100720.
16. Zlei M, Egert S, Wider D, Ihorst G, Wasch R, Engelhardt M. Characterization of in vitro growth of multi-
ple myeloma cells. Experimental hematology. 2007; 35(10):1550–61. Epub 2007/09/25. doi: 10.1016/j.
exphem.2007.06.016 PMID: 17889722.
17. Anderson KC. New insights into therapeutic targets in myeloma. Hematology Am Soc Hematol Educ
Program. 2011:184–90. Epub 2011/12/14. doi: 2011/1/184 [pii] doi: 10.1182/asheducation-2011.1.184
PMID: 22160032.
18. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, et al. Bortezomib-resistant
nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008; 6(8):1356–64. Epub
2008/08/19. doi: 10.1158/1541-7786.MCR-08-0108 PMID: 18708367; PubMed Central PMCID:
PMC2587345.
19. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of
bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of
PSMB5 protein. Blood. 2008; 112(6):2489–99. Epub 2008/06/21. doi: 10.1182/blood-2007-08-104950
PMID: 18565852.
20. Xu D, Hu J, De Bruyne E, Menu E, Schots R, Vanderkerken K, et al. Dll1/Notch activation contributes to
bortezomib resistance by upregulating CYP1A1 in multiple myeloma. Biochem Biophys Res Commun.
2012; 428(4):518–24. Epub 2012/11/01. doi: 10.1016/j.bbrc.2012.10.071 PMID: 23111325.
8p21 Deletion Confers Bortezomib Resistance in Multiple Myeloma
PLOSONE | DOI:10.1371/journal.pone.0138248 September 17, 2015 14 / 16
21. Ling X, Calinski D, Chanan-Khan AA, Zhou M, Li F. Cancer cell sensitivity to bortezomib is associated
with survivin expression and p53 status but not cancer cell types. Journal of experimental & clinical can-
cer research: CR. 2010; 29:8. Epub 2010/01/26. doi: 10.1186/1756-9966-29-8 PMID: 20096120;
PubMed Central PMCID: PMC2826345.
22. Surget S, Chiron D, Gomez-Bougie P, Descamps G, Menoret E, Bataille R, et al. Cell death via DR5,
but not DR4, is regulated by p53 in myeloma cells. Cancer research. 2012; 72(17):4562–73. doi: 10.
1158/0008-5472.CAN-12-0487 PMID: 22738917.
23. HuWH, Johnson H, Shu HB. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal
NF-kappaB and JNK activation and apoptosis through distinct pathways. The Journal of biological
chemistry. 1999; 274(43):30603–10. Epub 1999/10/16. PMID: 10521444.
24. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death
and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in humanmelanoma cells.
Journal of immunology. 2000; 164(8):3961–70. Epub 2001/02/07. PMID: 10754286.
25. An J, Sun Y, Fisher M, Rettig MB. Maximal apoptosis of renal cell carcinoma by the proteasome inhibi-
tor bortezomib is nuclear factor-kappaB dependent. Molecular cancer therapeutics. 2004; 3(6):727–36.
Epub 2004/06/24. PMID: 15210859.
26. Smith AJ, Dai H, Correia C, Takahashi R, Lee SH, Schmitz I, et al. Noxa/Bcl-2 protein interactions con-
tribute to bortezomib resistance in human lymphoid cells. The Journal of biological chemistry. 2011;
286(20):17682–92. Epub 2011/04/02. doi: 10.1074/jbc.M110.189092 PMID: 21454712; PubMed Cen-
tral PMCID: PMC3093844.
27. Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, et al. Bortezomib mitigates
adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple mye-
loma. Leukemia & lymphoma. 2012; 53(6):1174–82. Epub 2011/11/08. doi: 10.3109/10428194.2011.
637212 PMID: 22054286.
28. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor
TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incom-
plete death domain. Immunity. 1997; 7(6):813–20. Epub 1998/01/16. PMID: 9430226.
29. Morales JC, Ruiz-Magana MJ, Ruiz-Ruiz C. Regulation of the resistance to TRAIL-induced apoptosis
in human primary T lymphocytes: role of NF-kappaB inhibition. Molecular immunology. 2007; 44
(10):2587–97. Epub 2007/01/30. doi: 10.1016/j.molimm.2006.12.015 PMID: 17257681.
30. Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, et al. Myc regulates aggre-
some formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib
and SAHA. Blood. 2008; 112(7):2917–26. Epub 2008/07/22. doi: 10.1182/blood-2007-12-130823
PMID: 18641367; PubMed Central PMCID: PMC2556625.
31. Holien T, Sundan A. Oncogene addiction to c-MYC in myeloma cells. Oncotarget. 2012; 3(8):739–40.
Epub 2012/09/12. PMID: 22964579; PubMed Central PMCID: PMC3478451.
32. Holien T, Vatsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood.
2012; 120(12):2450–3. Epub 2012/07/19. doi: 10.1182/blood-2011-08-371567 PMID: 22806891.
33. Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB, et al. p53 haploinsufficiency and functional
abnormalities in multiple myeloma. Leukemia. 2014; 28(10):2066–74. doi: 10.1038/leu.2014.102
PMID: 24625551.
34. Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, et al. The MMSET histone
methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple
myeloma cells. Blood. 2011; 117(1):211–20. doi: 10.1182/blood-2010-07-298349 PMID: 20974671;
PubMed Central PMCID: PMC3037745.
35. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, et al. The proteasome inhibitor PS-341 (bortezomib)
up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced
apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer
research. 2007; 67(10):4981–8. Epub 2007/05/19. doi: 10.1158/0008-5472.CAN-06-4274 PMID:
17510429.
36. Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL
receptor DR5 mRNA through the 3'-untranslated region. Molecular cancer therapeutics. 2008; 7
(5):1091–100. Epub 2008/05/17. doi: 10.1158/1535-7163.MCT-07-2368 PMID: 18483298; PubMed
Central PMCID: PMC3632452.
37. Fulda S. Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
Oncotarget. 2011; 2(5):418–21. Epub 2011/07/27. PMID: 21789791; PubMed Central PMCID:
PMC3248183.
38. Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. Proteasome inhibition sup-
presses essential immune functions of human CD4+ T cells. Immunology. 2008; 124(2):234–46. Epub
8p21 Deletion Confers Bortezomib Resistance in Multiple Myeloma
PLOSONE | DOI:10.1371/journal.pone.0138248 September 17, 2015 15 / 16
2008/01/26. doi: 10.1111/j.1365-2567.2007.02761.x PMID: 18217957; PubMed Central PMCID:
PMC2566628.
39. Feng X, Yan J, Wang Y, Zierath JR, Nordenskjold M, Henter JI, et al. The proteasome inhibitor bortezo-
mib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural
killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Molecular immunology. 2010;
47(14):2388–96. Epub 2010/06/15. doi: 10.1016/j.molimm.2010.05.003 PMID: 20542572.
40. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. lenalidomide enhances natural killer cell
and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor
cells. Clinical cancer research: an official journal of the American Association for Cancer Research.
2008; 14(14):4650–7. Epub 2008/07/17. doi: 10.1158/1078-0432.CCR-07-4405 PMID: 18628480.
41. Jungkunz-Stier I, Zekl M, Stuhmer T, Einsele H, Seggewiss-Bernhardt R. Modulation of natural killer
cell effector functions through lenalidomide/dasatinib and their combined effects against multiple mye-
loma cells. Leukemia & lymphoma. 2014; 55(1):168–76. Epub 2013/04/12. doi: 10.3109/10428194.
2013.794270 PMID: 23573828.
8p21 Deletion Confers Bortezomib Resistance in Multiple Myeloma
PLOSONE | DOI:10.1371/journal.pone.0138248 September 17, 2015 16 / 16
